A phase II study of palliative radiotherapy combined with zoledronic acid hydrate for metastatic bone tumour from renal cell carcinoma
ConclusionZoledronic acid hydrate administration and palliative radiotherapy were a well-tolerated and promising treatment reducing skeletal-related events for bone metastases from renal cell carcinoma.
Source: Japanese Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Back Pain | Brain | Cancer & Oncology | Carcinoma | Japan Health | Kidney Cancer | Neurology | Orthopaedics | Pain | Palliative | Reclast | Renal Cell Carcinoma | Study | Toxicology | Zometa